Lineage Cell Therapeutics, Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission on March 11, 2026, announcing that it may offer up to $100 million of common shares, preferred shares, debt securities, and warrants in one or more offerings.
The supplement allows the company to issue any combination of the securities described, giving it the flexibility to tailor the mix to market conditions and investor demand. The prospectus also notes that the company may issue warrants, which could provide additional upside for investors if the company’s stock price rises, and it can issue debt or preferred shares to balance risk and return.
The financing is intended to support Lineage’s allogeneic cell‑therapy platform and to extend its cash runway as it advances programs such as OpRegen, OPC1, and ReSonance. Earlier this month the company announced an at‑the‑market offering of up to $60 million in common shares, and the new supplement excludes shares already sold under prior supplements, including $22,583,663.82 in gross proceeds that were previously raised.
Management highlighted the financial context in the Q4 2025 earnings call: “This is a significantly higher runway than we guided to during our last call, with the biggest contributors being the $21 million in gross proceeds received from an ATM block trade in November, the warrant exercise of $5.4 million this week along with the achievement of the first $5 million milestone under our Roche collaboration.” The company’s net loss widened to $63.5 million for the full year, but revenue grew to $14.6 million, and the combination of warrant exercises, milestone payments, and ATM proceeds has extended the runway to Q2 2028.
The prospectus supplement provides Lineage with the flexibility to raise capital as needed, allowing it to adjust the mix of securities to market conditions and investor demand. This flexibility supports the company’s pipeline and maintains operational flexibility, positioning it to capitalize on clinical milestones and collaboration opportunities without immediate dilution or debt burden.
The filing is a routine shelf registration update, but it signals that Lineage remains focused on advancing its pipeline and maintaining financial resilience in a capital‑intensive biopharma environment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.